Skip to content

The effects of adding ozone to the dextrose and uotropin intraarticular ln knee osteoarthritis

Compared the effects of adding ozone to dextrose and uotropin with only dextrose and uotropin intra knee for the pain control and improvement activites in the knee osteoarthritis.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201410187984N20
Enrollment
56
Registered
2015-01-04
Start date
2013-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Knee Osteoarthritis. Condition 2: Knee Osteoarthritis. Other Arthritis Arthropathy in other diseases

Interventions

Intervention 1: Intervention group : 10 cc dextrose 50% plus 4 unit uotropin and 10 cc ozone 25 microgram is injected into the knee. Intervention 2: Control group : 10 cc dextrose 50% and 4
Treatment - Other
Treatment - Drugs
Intervention group : 10 cc dextrose 50% plus 4 unit uotropin and 10 cc ozone 25 microgram is injected into the knee.
Control group : 10 cc dextrose 50% and 4 unit uotropin is injected into the knee.

Sponsors

Vice chancellor for research, Iran University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion citeria: 1, 25-70 years old patients with primary Osteoarthritis attended in clinic or pain section were selected for the experiment. 2, considering general criteria the patient were belonged to ASA 1-2. 3, Before the onset of experiment the volunteer patients were asked to sign an agreement supplied by the Moral Committee of the Iran University of Medical Science. 4, Accurate visit of the recognition of the primary Osteoarthritis symptoms was accomplished based on the American Rheumatology Association standards. Exclusion criteria: 1, Alchol and opium addiction. 2, Hemophilia. 3, Rheumatoid Arthritis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: First, third and fifth weeks after the first injection and four months after the last injection. Method of measurement: VAS.

Secondary

MeasureTime frame
Range of motion and knee stiffness. Timepoint: First, third and fifth weeks after the last injection and four months after the last injection. Method of measurement: WOMAC score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farnad Imani

Rasoul Akram Hospital

farimani@tums.ac.ir+98 21 6435 2107

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026